2024 Biosimilars Pharmaceutical Manufacturing 
Express Pharma
NOVEMBER 13, 2024
The 17th edition of CPHI & PMEC India, organised by Informa Markets in India, returns in an advanced format, scheduled from November 26-28, 2024, at the India Expo Centre, Greater Noida, Delhi-NCR. India’s pharma industry is on an impressive growth trajectory, expected to reach $65 billion by 2024 and to double to $130 billion by 2030.
Express Pharma
NOVEMBER 26, 2024
Integrating IT with pharmaceuticals will further strengthen its role, paving the way for dominance in biologics and biosimilars. The day concluded with the prestigious India Pharma Awards 2024, celebrating outstanding achievements in innovation and excellence within the pharmaceutical industry. With exports nearing $27.84
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Channels
JULY 23, 2024
It’s time for Drug Channels ’ annual update on pricing at the largest pharmaceutical manufacturers. Insulin has been the first to deflate—and the Humira biosimilar market may be next. Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. All rights reserved.
Express Pharma
NOVEMBER 18, 2024
The 17th edition of CPHI & PMEC India, organised by Informa Markets in India, will take place from 26th to 28th November 2024 at the India Expo Centre, Greater Noida, Delhi-NCR. The event will showcase developments in pharmaceutical modernisation, innovation, and sustainability.
FDA Law Blog: Biosimilars
JUNE 24, 2024
The event, titled “New and Improved – AMCP Format for Formulary Submissions v5.0,” aims to educate pharmaceutical manufacturers and other healthcare stakeholders on the latest updates and best practices in dossier development. released in April 2024, marks the first update since 2020. The latest iteration, version 5.0,
FDA Law Blog: Biosimilars
AUGUST 14, 2024
Gaulkin — Enacted in 2022, the Inflation Reduction Act (IRA) amended the Medicare provisions of the Social Security Act to impose several discount requirements on pharmaceutical manufacturers. On July 31, 2024, CMS published a proposed rule to codify its guidances, with some changes.
FDA Law Blog: Biosimilars
MAY 30, 2024
Kirschenbaum — Last week, the United States Court of Appeals for the District of Columbia ruled that Section 340B of the Public Health Service Act does not prohibit pharmaceutical manufacturers from imposing conditions on the distribution of discounted drugs to covered entities in the program. In United Therapeutics Corporation v.
Expert insights. Personalized for you.
105 
Let's personalize your content